Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a single arm study to evaluate the safety and efficiency of azacitidine (AZA)
combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia.
Azacitidine, venetoclax and ATRA, may stop the growth of cancer cells, either by
demethylation, by promoting cells differentiation or by killing the cells.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University